瑞普生物(300119) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥593,068,520.22, representing a 4.34% increase compared to the same period last year[5]. - Net profit attributable to shareholders was ¥95,426,859.38, up 2.40% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥81,132,930.17, an increase of 0.50%[5]. - Total operating revenue for the current period reached ¥1,587,164,776.49, an increase of 7.5% compared to ¥1,476,760,957.48 in the previous period[28]. - Net profit for the current period was ¥294,900,963.96, representing a 15.3% increase from ¥256,016,202.77 in the same period last year[29]. - The company reported a total comprehensive income of ¥294,900,963.96, an increase from ¥256,016,202.77 in the same period last year[30]. - Earnings per share (EPS) improved to ¥0.5900, compared to ¥0.5036 in the previous year[30]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥6,218,503,041.23, reflecting a 1.84% increase from the end of the previous year[5]. - Current assets totaled CNY 3,038,546,011.31, a decrease from CNY 3,093,291,712.42 at the beginning of the year[24]. - The company’s total liabilities decreased to CNY 1,572,707,220.68 from CNY 1,605,173,462.21 at the beginning of the year[26]. - The ending balance of cash and cash equivalents was 382,399,123.95, down from 620,788,270.41 year-over-year[34]. Cash Flow - Cash flow from investment activities was ¥159,367,086.50, a 116.73% increase, primarily due to the redemption of financial products and increased investment income[10]. - Cash inflow from investment activities totaled ¥2,756,212,231.59, a significant increase from ¥1,583,477,199.71 year-over-year[33]. - Cash flow from operating activities generated a net amount of ¥196,967,341.28, slightly down from ¥200,918,377.93 in the prior period[33]. - The net cash flow from financing activities showed a significant decline, amounting to -¥350,695,043.06, a decrease of 481.22% due to the repayment of bank loans[10]. Research and Development - Research and development expenses surged to ¥124,183,791.04, marking a 66.84% increase, driven by enhanced R&D efforts and talent acquisition[9]. - Research and development expenses increased significantly to ¥124,183,791.04, a rise of 67% from ¥74,433,917.50 year-over-year[28]. - The company has developed a new inactivated vaccine for cats, which has passed emergency evaluation by the Ministry of Agriculture and Rural Affairs[17]. - The company obtained two new veterinary drug registration certificates, enhancing its product matrix in bacterial genetic engineering vaccines and disinfection, creating new profit growth points[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,890[12]. - The largest shareholder, Li Shoujun, holds 35.92% of shares, totaling 167,474,479 shares, with 48,500,000 shares pledged[12]. - The company has 125,605,859 shares under lock-up for executives, which will remain until the end of the lock-up period[15]. - The top ten shareholders include various institutional and individual investors, with significant pledges noted[12]. - The controlling shareholder and actual controller committed not to reduce their holdings in the company for six months, reflecting confidence in the company's future development[19]. Operational Developments - The company is actively organizing trial production and applying for temporary approval for the new veterinary drug[17]. - The company is focused on expanding its product offerings and market presence in the veterinary sector[17]. - The company’s subsidiary, Hunan Zhong'an, sold part of its assets to enhance asset liquidity and positively impact operational results[21]. Other Financial Metrics - The weighted average return on net assets was 2.21%, a slight decrease of 0.08% compared to the previous year[5]. - The company’s total equity attributable to shareholders increased to ¥4,360,872,233.93, up 3.30% from the end of the previous year[5]. - The company experienced a 271.88% increase in notes receivable, reaching ¥14,797,012.02, attributed to increased note business during the period[9]. - The adjustment of deferred tax liabilities was from 52,443,981.15 to 52,437,603.03 due to the new accounting standards implemented in 2023[36]. - The adjustment of payable taxes increased slightly from 47,476,720.17 to 47,483,098.29[36]. Stock and Capital Changes - The company completed the repurchase and cancellation of 1.7426 million restricted stock options, resulting in a total share capital of 466,276,186 shares[22]. - The total number of restricted shares at the beginning of the period was 133,711,900, with 1,742,600 shares released during the period[16]. - The company has a total of 131,979,425 restricted shares remaining after the recent adjustments[16]. Audit Status - The third quarter report was not audited[37].